However, since the IGF-1R is key to biological pathways involved in the aging process and age-related diseases, additional work is needed to investigate the effect of chronic administration of PPP or other pharmacologic IGF-1R inhibitors on the progression of AD. This evidence concerns the gene IGF1R and Alzheimer disease.